20th Jun 2016 06:20
LONDON (Alliance News) - GlaxoSmithKline PLC on Monday said it has received positive top-line results from the phase three study conducted on its chronic obstructive pulmonary disease treatment.
The FTSE 100 drugmaker said its fluticasone furoate/umeclidinium/vilanterol triple combination therapy met its two co-primary endpoints. This included showing statistically significant improvements against a twice-day dose of Symbicort, a rival treatment, in both lung function and health-related quality of life.
"We are delighted with the outcome of the FULFIL study, which marks a further step towards making this closed triple combination therapy available to appropriate patients with COPD. Triple combination therapy is already a reality for many patients with COPD and is dispensed in multiple inhalers. By combining three medicines in a single inhaler we can offer a convenient, once-daily dosing option to patients while improving their symptoms," said Dave Allen, head of respiratory research and development at Glaxo.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline